{"title":"Prognostic Value of Spontaneous Potential in Left Atrial Posterior Wall Isolation and Radiofrequency Ablation for Non-Paroxysmal Atrial Fibrillation.","authors":"Zhi-Yang Chen, Yu-Hong Zhong, Ke-Zeng Gong, Xue-Hai Chen, Zhe Xu, Fei-Long Zhang","doi":"10.2147/TCRM.S525135","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to examine the long-term effects of left atrial posterior wall spontaneous potential (SP) in patients with non-paroxysmal atrial fibrillation (AF) who underwent pulmonary vein isolation (PVI) combined with left atrial posterior wall isolation (PVI+BOX) ablation.</p><p><strong>Methods: </strong>Clinical data were retrospectively collected from 140 patients with symptomatic non-paroxysmal atrial fibrillation (NPAF) who underwent first-time radiofrequency ablation between 2022 and 2023. Based on the surgical procedure, patients were categorized into the pulmonary vein isolation group (PVI group) and the pulmonary vein isolation + left atrial posterior wall isolation group (PVI+BOX group). The PVI+BOX group was further subdivided into the spontaneous potential group (SP group) and the no-spontaneous potential group (no-SP group) based on the presence of SP after left atrial posterior wall isolation. Patients underwent monthly follow-ups in the clinic or via telephone and received 72-hour dynamic electrocardiography (ECG) at 3 and 12 months postoperatively. AF recurrence was compared among the groups, and factors associated with recurrence following AF ablation were analyzed.</p><p><strong>Results: </strong>The PVI+BOX group included 78 cases, with 45 in the no-SP group and 33 in the SP group, while the PVI group comprised 62 cases. No significant difference was observed in the postoperative recurrence-free rate between the PVI+BOX and PVI groups. However, the SP group exhibited a higher postoperative recurrence-free rate compared to both the no-SP group (<i>p</i> = 0.039) and the PVI group (<i>p</i> = 0.020). No significant difference was found in the late recurrence-free rate between the no-SP and PVI groups. Multivariate logistic regression analysis indicated that the duration of AF and the presence of left atrial posterior wall SP were independent risk factors for post-ablation recurrence in patients with NPAF.</p><p><strong>Conclusion: </strong>The presence of SP post-left atrial posterior wall isolation suggests a better long-term outcome in patients with NPAF following PVI+BOX catheter ablation.</p>","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"1021-1031"},"PeriodicalIF":2.8000,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12239905/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutics and Clinical Risk Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/TCRM.S525135","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: This study aimed to examine the long-term effects of left atrial posterior wall spontaneous potential (SP) in patients with non-paroxysmal atrial fibrillation (AF) who underwent pulmonary vein isolation (PVI) combined with left atrial posterior wall isolation (PVI+BOX) ablation.
Methods: Clinical data were retrospectively collected from 140 patients with symptomatic non-paroxysmal atrial fibrillation (NPAF) who underwent first-time radiofrequency ablation between 2022 and 2023. Based on the surgical procedure, patients were categorized into the pulmonary vein isolation group (PVI group) and the pulmonary vein isolation + left atrial posterior wall isolation group (PVI+BOX group). The PVI+BOX group was further subdivided into the spontaneous potential group (SP group) and the no-spontaneous potential group (no-SP group) based on the presence of SP after left atrial posterior wall isolation. Patients underwent monthly follow-ups in the clinic or via telephone and received 72-hour dynamic electrocardiography (ECG) at 3 and 12 months postoperatively. AF recurrence was compared among the groups, and factors associated with recurrence following AF ablation were analyzed.
Results: The PVI+BOX group included 78 cases, with 45 in the no-SP group and 33 in the SP group, while the PVI group comprised 62 cases. No significant difference was observed in the postoperative recurrence-free rate between the PVI+BOX and PVI groups. However, the SP group exhibited a higher postoperative recurrence-free rate compared to both the no-SP group (p = 0.039) and the PVI group (p = 0.020). No significant difference was found in the late recurrence-free rate between the no-SP and PVI groups. Multivariate logistic regression analysis indicated that the duration of AF and the presence of left atrial posterior wall SP were independent risk factors for post-ablation recurrence in patients with NPAF.
Conclusion: The presence of SP post-left atrial posterior wall isolation suggests a better long-term outcome in patients with NPAF following PVI+BOX catheter ablation.
期刊介绍:
Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas.
The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature.
As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication.
The journal does not accept study protocols, animal-based or cell line-based studies.